ZAI LAB LIMITED Basic Shares Outstanding (Weighted Average)
ZAI LAB LIMITED (ZLAB) reported Basic Shares Outstanding (Weighted Average) of 1.12 billion shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- ZAI LAB LIMITED weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 1.12B shares, a 2.29% increase year-over-year.
- ZAI LAB LIMITED weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 1.11B shares, a 2.46% increase year-over-year.
- ZAI LAB LIMITED weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 1.11B shares, a 7.70% increase year-over-year.
- ZAI LAB LIMITED weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 1.10B shares, a 12.26% increase year-over-year.
- ZAI LAB LIMITED weighted average number of shares outstanding, basic for fiscal 2025 was 1.10B shares, a 10.70% increase from fiscal 2024.
- ZAI LAB LIMITED weighted average number of shares outstanding, basic for fiscal 2024 was 989.48M shares, a 2.39% increase from fiscal 2023.
- ZAI LAB LIMITED weighted average number of shares outstanding, basic for fiscal 2023 was 966.39M shares, a 0.87% increase from fiscal 2022.
- ZAI LAB LIMITED weighted average number of shares outstanding, basic for fiscal 2022 was 958.07M shares, a 3.03% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.12B shares 10-Q · filed 2026-08-06 | 1.11B shares 10-Q · filed 2026-08-06 | 1.11B shares derived: average of 3 quarters · filed 2026-08-06 | 1.11B shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 1.11B shares 10-Q · filed 2026-05-07 | 1.11B shares derived: average of 2 quarters · filed 2026-05-07 | 1.11B shares derived: average of 3 quarters · filed 2026-05-07 | 1.10B shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 1.11B shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 1.10B shares derived: average of 2 quarters · filed 2026-02-26 | 1.10B shares derived: average of 3 quarters · filed 2026-08-06 | 1.10B shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 1.10B shares 10-Q · filed 2025-11-06 | 1.10B shares derived: average of 2 quarters · filed 2026-08-06 | 1.09B shares 10-Q · filed 2025-11-06 | 1.08B shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 1.09B shares 10-Q · filed 2026-08-06 | 1.09B shares 10-Q · filed 2026-08-06 | 1.07B shares derived: average of 3 quarters · filed 2026-08-06 | 1.05B shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 1.08B shares 10-Q · filed 2026-05-07 | 1.05B shares derived: average of 2 quarters · filed 2026-05-07 | 1.03B shares derived: average of 3 quarters · filed 2026-05-07 | 1.02B shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 1.03B shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 1.00B shares derived: average of 2 quarters · filed 2026-02-26 | 994.90M shares derived: average of 3 quarters · filed 2026-02-26 | 989.48M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 981.69M shares 10-Q · filed 2025-11-06 | 978.81M shares derived: average of 2 quarters · filed 2025-11-06 | 976.94M shares 10-Q · filed 2025-11-06 | 975.29M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 975.94M shares 10-Q · filed 2025-08-07 | 974.54M shares 10-Q · filed 2025-08-07 | 973.16M shares derived: average of 3 quarters · filed 2026-02-26 | 972.06M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 973.15M shares 10-Q · filed 2025-05-08 | 971.77M shares derived: average of 2 quarters · filed 2026-02-26 | 970.77M shares derived: average of 3 quarters · filed 2026-02-26 | 969.28M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 970.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 969.58M shares derived: average of 2 quarters · filed 2026-02-26 | 967.99M shares derived: average of 3 quarters · filed 2026-02-26 | 966.39M shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 968.77M shares 10-Q · filed 2024-11-12 | 966.79M shares derived: average of 2 quarters · filed 2024-11-12 | 965.06M shares 10-Q · filed 2024-11-12 | 963.74M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | 964.82M shares 10-Q · filed 2024-08-06 | 963.14M shares 10-Q · filed 2024-08-06 | 962.07M shares derived: average of 3 quarters · filed 2025-02-27 | 961.32M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | 961.44M shares 10-Q · filed 2024-05-08 | 960.70M shares derived: average of 2 quarters · filed 2025-02-27 | 960.16M shares derived: average of 3 quarters · filed 2025-02-27 | 959.54M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | 959.95M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 959.52M shares derived: average of 2 quarters · filed 2025-02-27 | 958.91M shares derived: average of 3 quarters · filed 2025-02-27 | 958.07M shares 10-K · filed 2025-02-27 |
| 2022-09-30 | 959.09M shares 10-Q · filed 2023-11-07 | 958.39M shares derived: average of 2 quarters · filed 2023-11-07 | 957.44M shares 10-Q · filed 2023-11-07 | 956.68M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 957.68M shares 10-Q · filed 2023-08-07 | 956.60M shares 10-Q · filed 2023-08-07 | 955.87M shares derived: average of 3 quarters · filed 2024-02-27 | 954.49M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 955.50M shares 10-Q · filed 2023-05-09 | 954.97M shares derived: average of 2 quarters · filed 2024-02-27 | 953.43M shares derived: average of 3 quarters · filed 2024-02-27 | 947.69M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 954.44M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 952.40M shares derived: average of 2 quarters · filed 2024-02-27 | 945.08M shares derived: average of 3 quarters · filed 2024-02-27 | 929.92M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 950.35M shares 10-Q · filed 2022-11-09 | 940.40M shares derived: average of 2 quarters · filed 2022-11-09 | 921.75M shares 10-Q · filed 2022-11-09 | |
| 2021-06-30 | 930.46M shares 10-Q · filed 2022-08-09 | 907.23M shares 10-Q · filed 2022-08-09 | ||
| 2020-12-31 | 776.68M shares 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |